BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 27, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
BioWorld Science, Cancer RSS Feed RSS

Cancer

Korean researchers patent new prostanoid EP2 and EP4 receptor dual antagonists for cancer

Sep. 19, 2023
Researchers from Kanaph Therapeutics Inc. and Korea Research Institute of Chemical Technology have disclosed prostanoid EP2 and/or EP4 receptor subtype dual antagonists reported to be useful for the treatment of cancer.
Read More
Immuno-oncology

Pharmabcine’s anti-VISTA antibody PMC-309 receives Australian HREC clearance for phase I study in solid tumors

Sep. 19, 2023
Pharmabcine Inc. has received approval from the human research ethics committee (HREC) in Australia for a phase Ia/b trial of PMC-309, a monoclonal antibody against the human V-domain Ig suppressor of T-cell activation (VISTA) ligand.
Read More
Cancer

Potent AR antagonist shows AR degrading activity and antitumor efficacy in prostate cancer models

Sep. 19, 2023
Researchers from China Pharmaceutical University and Nanjing First Hospital synthesized and optimized a novel series of thiohydantoin based compounds leading to the discovery of candidate [I] as the lead androgen receptor (AR) antagonist (IC50=1.46 µM).
Read More
Cancer cells under magnifying glass
Immuno-oncology

Kayothera selects retinoid pathway inhibitor as development candidate

Sep. 19, 2023
Kayothera Inc. has selected KAYO-1609, an oral retinoid pathway inhibitor, as its first drug development candidate.
Read More
Cancer

Cancer Research Technology patents new PROTACs targeting ERK5 for cancer

Sep. 18, 2023
Cancer Research Technology Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently bonded to a mitogen-activated protein kinase 7 (MAPK7; ERK5)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Read More
Photomicrograph of hepatocellular carcinoma
Cancer

TMHA-37, a potent Nur77 modulator with cytotoxicity against HCC cell lines

Sep. 18, 2023
Researchers from Xiamen University and affiliated organizations have reported the discovery of nuclear hormone receptor NUR/77 (Nur77) modulators as potential candidates for the treatment of hepatocellular carcinoma (HCC).
Read More
Pancreas
Diagnostics

Researchers present [124I]IMMU-132, a Trop2-targeting PET probe

Sep. 18, 2023
Researchers from Peking University Cancer Hospital presented the discovery and preclinical evaluation of [124I]IMMU-132, a trophoblast cell surface antigen 2 (Trop2)-targeting molecular probe for micro-PET imaging.
Read More
Cancer cells
Diagnostics

[177Lu]NGR-RGD-AB, a novel albumin binder radiolabeled heterodimer for theranostic use

Sep. 18, 2023
Integrin alphavbeta3 and aminopeptidase N (CD13) are important biomarkers involved in tumor angiogenesis, tumor growth and metastasis. Peptides RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) are the most studied peptides for targeting integrin alphavbeta3 and CD13, respectively.
Read More
Cancer cells being destroyed by immunotherapy
Immuno-oncology

Medigene selects lead candidate for TCR-T therapy program MDG-2011

Sep. 18, 2023
Medigene AG has selected its lead candidate for MDG-2011, a T-cell receptor engineered T-cell (TCR-T) therapy targeting KRAS G12V with HLA-A*11 and being developed in combination with the company’s PD1-41BB costimulatory switch protein (CSP) technology.
Read More
Cancer

IRX-4647 promotes anticancer immune response in combination treatments

Sep. 18, 2023
Retinoic acid (RA) is fundamental to maintain immune homeostasis. In this process, RA induces regulatory T cells and promotes tolerance, but depending on the conditions, RA may also promote inflammation and tissue damage.
Read More
Previous 1 2 … 432 433 434 435 436 437 438 439 440 … 3709 3710 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2026.
  • Blue brain with computer chip

    Have brain-computer interfaces finally arrived?

    BioWorld
    More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 23, 2026
  • Cortec Brain Interchange BCI system

    Brain-computer interfaces are here but long road ahead

    BioWorld
    The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
  • Patient using Neuracle NEO system

    2026 marks critical turning point for BCI technology

    BioWorld
    Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing